Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | SYK | P43405 | 8/20 | 0.92 |
| ▸ | AURKA | O14965 | 6/20 | 0.65 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29523904 | 1.00 | BTK (1.00) | BTKSYKAURKAEPHB4ALDH1A1 | |
| SCHEMBL2218484 | 0.96 | SYK (1.00) | BTKSYKAURKAEPHB4 | |
| SCHEMBL2219062 | 0.95 | BTK (0.90) | BTKSYKAURKAEPHB4 | |
| SCHEMBL4816119 | 0.94 | BTK (0.89) | BTKSYKAURKAEPHB4 | |
| SCHEMBL6002791 | 0.94 | BTK (0.89) | BTKSYKAURKAEPHB4 | |
| SCHEMBL4811490 | 0.94 | BTK (0.89) | BTKSYKAURKAEPHB4 | |
| SCHEMBL2216718 | 0.94 | BTK (0.89) | BTKSYKAURKAEPHB4 | |
| SCHEMBL4808482 | 0.94 | BTK (0.88) | BTKSYKAURKAEPHB4ALDH1A1 | |
| SCHEMBL2217123 | 0.93 | BTK (0.87) | BTKSYKAURKAEPHB4 | |
| SCHEMBL2218534 | 0.93 | BTK (0.87) | BTKSYKAURKAEPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 806 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4378957-A2 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | Novartis AG (CH) | 2024-06-05 | — | — | EP | claimed |
| EP-3888674-B1 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2024-04-03 | — | — | EP | claimed |
| US-20240016840-A1 | METHODS AND COMPOSITIONS FOR USE OF THERAPEUTIC T CELLS IN COMBINATION WITH KINASE INHIBITORS | JUNO THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | claimed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | claimed |
| US-11648255-B2 | Inhibitors for treatment of hematological malignancies | MASARYKOVA UNIVERZITA (CZ) | 2023-05-16 | — | — | US | claimed |
| WO-2022232420-A1 | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CANCER | INSMED INCORPORATED (US) | 2022-11-03 | — | — | WO | claimed |
| US-20220241261-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-08-04 | — | — | US | claimed |
| US-20180289685-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-11 | — | — | US | claimed |
| EP-3195865-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-26 | — | — | EP | claimed |
| US-7405295-B2 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | claimed |
| US-20060183746-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. | 2006-08-17 | — | — | US | claimed |
| US-20050090499-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds | GILEAD CONNECTICUT, INC. | 2005-04-28 | — | — | US | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-3325504-B1 | METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF IMMUNE CELLS | NOVARTIS AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-3523331-B1 | CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | NOVARTIS AG (CH) | 2026-05-19 | — | — | US | disclosed |
| US-7405295-B2 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060183746-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. | 2006-08-17 | — | — | US | disclosed |
| US-20050090499-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds | GILEAD CONNECTICUT, INC. | 2005-04-28 | — | — | US | disclosed |
| WO-2005014599-A1 | IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHOD OF INHIBITION OF BRUTON’S TYROSINE KINASE BY SUCH COMPOUNDS | CELLULAR GENOMICS, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090499-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds | BTK, SYK, JAK1 | BTK 1/4885SYK 2/4885AURKA 197/4885 |
| US-20240016840-A1 | METHODS AND COMPOSITIONS FOR USE OF THERAPEUTIC T CELLS IN COMBINATION WITH KINASE INHIBITORS | ITK, PBK, BMX | BTK 10/4885SYK 46/4885AURKA 373/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | BTK 398/4885SYK 528/4885AURKA 3406/4885 |
| US-20180289685-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | IRAK4, IRAK1, IRAK2 | BTK 5/4885SYK 12/4885AURKA 615/4885 |
| US-20220241261-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | IRAK4, IRAK2, IRAK1 | BTK 6/4885SYK 12/4885AURKA 731/4885 |
| US-11648255-B2 | Inhibitors for treatment of hematological malignancies | GAB1, BTK, MCL1 | BTK 2/4885SYK 30/4885AURKA 2050/4885 |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | CD40, CD274, ICOS | BTK 28/4885SYK 166/4885AURKA 833/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | BTK 55/4885SYK 736/4885AURKA 347/4885 |
| US-20060183746-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | BTK, SYK, LCK | BTK 1/4885SYK 2/4885AURKA 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.